Peripheral natural killer cell and allo-stimulated T-cell function in kidney transplant recipients associate with cancer risk and immunosuppression-related complications

Kidney International

Volumn 88, Issue 6, 2015, Pages 1374-1382

  Hope, Christopher M ^a,b   Troelnikov, Alexander ^a,b   Hanf, William ^a   Jesudason, Shilpanjali ^a,b   Coates, Patrick T ^a,b   Heeger, Peter S ^c   Carroll, Robert P ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; IFN ELISPOT; Immunosuppression; Kidney transplantation; NK cells

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; GAMMA INTERFERON; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; ALLOIMMUNITY; ARTICLE; CANCER MORTALITY; CANCER RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME RELEASE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NATURAL KILLER CELL; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEPSIS; T LYMPHOCYTE ACTIVATION;

EID: 84951568204     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.237     Document Type: Article

References (37)

1. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691
2. Euvrard S, Kanitakis J, Decullier E et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81: 1093-1100
3. Moloney FJ, Comber H, O'Lorcain P et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154: 498-504
4. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-2831
5. Wisgerhof HC, van der Geest LG, de Fijter JW et al. Incidence of cancer in kidney-transplant recipients: a long-term cohort study in a single center. Cancer Epidemiol 2011; 35: 105-111
6. Hope CM, Coates PTH, Carroll RP. Immune profiling and cancer post transplantation. World J Nephrol 2015; 4: 41-56
7. Wisgerhof HC, Edelbroek JR, de Fijter JW et al. Subsequent squamous-and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 2010; 89: 1231-1238
8. Tessari G, Naldi L, Boschiero L et al. Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. Am J Transplant 2013; 13: 214-221
9. Stasko T, Brown MD, Carucci JA et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004; 30: 642-650
10. Carroll RP, Hester J, Wood KJ et al. Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype. Nephrol Dial Transplant 2013; 28: 462-465
11. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628
12. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 2013; 31: 1317-1323
13. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589
14. Euvrard S, Morelon E, Rostaing L et al. Sirolimus and secondary skincancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329-339
15. Poggio ED, Augustine JJ, Clemente M et al. Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 2007; 83: 847-852
16. Sanchez-Fructuoso A, Conesa J, Perez Flores I et al. Conversion to sirolimus in renal transplant patients with tumors. Transplant Proc 2006; 38: 2451-2452
17. Eng HS, Bennett G, Tsiopelas E et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008; 8: 2335-2342
18. Carroll RP, Segundo DS, Hollowood K et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol 2010; 21: 713-722
19. Hope CM, Grace BS, Pilkington KR et al. The immune phenotype may relate to cancer development in kidney transplant recipients. Kidney Int 2014; 86: 175-183
20. Alamartine E, Sabido O, Berthoux FC. The low number of natural killer cells in renal transplant recipients with de novo malignancies. Transplantation 1992; 54: 569-571
21. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1988; 115: 61-69
22. Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513
23. Poggio ED, Clemente M, Hricik DE et al. Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol 2006; 17: 564-572
24. Bavinck JN, Tieben LM, Van der Woude FJ et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933-1938
25. Otley CC, Coldiron BM, Stasko T et al. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001; 137: 459-463
26. Moloney FJ, Kelly PO, Kay EW et al. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg 2004; 30: 674-678
27. Alberu J, Pascoe MD, Campistol JM et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011; 92: 303-310
28. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 2013; 31: 1317-1323
29. Kamar N, Del Bello A, Congy-Jolivet N et al. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. Clin Transplant 2013; 27: 455-462
30. Baumforth KR, Birgersdotter A, Reynolds GM et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008; 173: 195-204
31. Bergmann C, Strauss L, Wang Y et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008; 14: 3706-3715
32. Bergmann C, Strauss L, Zeidler R et al. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007; 67: 8865-8873
33. Uehara S, Chase CM, Kitchens WH et al. NK cells can trigger allograft vasculopathy: the role of hybrid resistance in solid organ allografts. J Immunol 2005; 175: 3424-3430
34. Maier S, Tertilt C, Chambron N et al. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/-mice. Nat Med 2001; 7: 557-562
35. McNerney ME, Lee KM, Zhou P et al. Role of natural killer cell subsets in cardiac allograft rejection. Am J Transplant 2006; 6: 505-513
36. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-1457
37. Zand MS, Bose A, Vo T et al. A renewable source of donor cells for repetitive monitoring of T-and B-cell alloreactivity. Am J Transplant 2005; 5: 76-86.